Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815033 | 0.98 | CRBN (0.31) | KMT2AMEN1CRBNDDB1 | |
| SCHEMBL19815096 | 0.95 | CRBN (0.31) | CRBNDDB1 | |
| SCHEMBL2159192 | 0.91 | CRBN (0.33) | CRBNDDB1 | |
| SCHEMBL19817308 | 0.83 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL17112824 | 0.81 | DDB1 (0.30) | CRBNDDB1 | |
| SCHEMBL17611698 | 0.77 | CRBN (0.40) | CRBNDDB1 | |
| SCHEMBL21197351 | 0.77 | USP30 (0.43) | KMT2AMEN1CRBNDDB1 | |
| SCHEMBL18321890 | 0.76 | SPR (0.36) | KMT2AMEN1CRBNDDB1 | |
| SCHEMBL4985158 | 0.74 | USP30 (0.44) | KMT2AMEN1CRBNDDB1 | |
| SCHEMBL5895840 | 0.74 | SPR (0.35) | HSD11B1CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| EP-3890829-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| US-11053213-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| WO-2020115501-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | KMT2A 2422/4885MEN1 2163/4885HSD11B1 727/4885 |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | KMT2A 1989/4885MEN1 3585/4885HSD11B1 1241/4885 |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | KMT2A 2422/4885MEN1 2163/4885HSD11B1 727/4885 |
| US-11053213-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | KMT2A 2422/4885MEN1 2163/4885HSD11B1 727/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | KMT2A 1484/4885MEN1 4318/4885HSD11B1 327/4885 |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | KMT2A 1484/4885MEN1 4318/4885HSD11B1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.